Isoxazole hydroxamic acid compounds as LpxC inhibitors
申请人:Novartis AG
公开号:US10029994B2
公开(公告)日:2018-07-24
This invention pertains generally to compounds of Formula I as described herein and compositions containing such compounds, as well as methods of using such compounds to treat bacterial infections. In certain aspects, the invention provides methods and compositions comprising these compounds for treating infections caused by Gram-negative bacteria.
本发明一般涉及本文所述的式 I 化合物和含有此类化合物的组合物,以及使用此类化合物治疗细菌感染的方法。 在某些方面,本发明提供了包含这些化合物的用于治疗革兰氏阴性细菌引起的感染的方法和组合物。
ISOXAZOLE HYDROXAMIC ACID COMPOUNDS AS LPXC INHIBITORS
申请人:Novartis AG
公开号:EP3233843A1
公开(公告)日:2017-10-25
US9549916B2
申请人:——
公开号:US9549916B2
公开(公告)日:2017-01-24
US9815804B2
申请人:——
公开号:US9815804B2
公开(公告)日:2017-11-14
[EN] ISOXAZOLE HYDROXAMIC ACID COMPOUNDS AS LPXC INHIBITORS<br/>[FR] COMPOSÉS D'ACIDES D'ISOXAZOLE EN TANT QU'INHIBITEURS DE LPXC
申请人:NOVARTIS AG
公开号:WO2016097995A1
公开(公告)日:2016-06-23
This invention pertains generally to compounds of Formula I as described herein and compositions containing such compounds, as well as methods of using such compounds to treat bacterial infections. In certain aspects, the invention provides methods and compositions comprising these compounds for treating infections caused by Gram-negative bacteria.